Bruna Custódio Dias Duarte

Bruna Custódio Dias Duarte

Auto-generated profile, based on publicly available information

Bruna Custódio Dias Duarte

Laboratório de Bioinformática e Análises Moleculares Universidade Federal de Uberlândia Patos de Minas Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2025 in Mário Penna Journal
Verified
Journal Article
Open access
BDBruna Custódio Dias Duarte
Bruna Custódio Dias Duarte
ANAngelo Borges de Melo Neto
Angelo Borges de Melo Neto
ÁCÁlvaro Percínio Costa
Álvaro Percínio Costa
CMCarolina Pereira de Souza Melo
Carolina Pereira de Souza Melo
PSPaulo G.O. Salles
Paulo G.O. Salles
FQFábio Ribeiro Queiroz
Fábio Ribeiro Queiroz
Introduction: Cervical cancer (CC) is one of the most common types of cancer in women and is closely associated with persistent infection by oncogenic types of the human papillomavirus (HPV). The World Health Organization (WHO) aims to eradicate CC as a public health problem by 2100. However, challenges such as vaccination limitations and the spread of misinformation hinder vaccine uptake, despite its proven efficacy (1). The prognosis of CC depends on the stage of the disease and becomes more unfavorable in advanced stages. Therefore, the search for effective biomarkers for diagnosis and monitoring is essential to improve early detection and treatment follow-up. Objectives: This study aimed to explore the role of long non-coding RNAs (lncRNAs) in CC, focusing on identifying and characterizing relevant lncRNAs, understanding their regulatory mechanisms and molecular interactions, and analyzing their expression patterns in patients with different responses to chemoradiotherapy. Methods: A retrospective observational study was conducted, analyzing RNA samples from 31 patients treated at the Mário Penna Institute (2017-2019) (2). The expression of lncRNAs was analyzed by RNA-seq, and molecular interactions were investigated using bioinformatics tools such as AnnoLnc2 and ClusterProfiler. Decision tree analyses and Kaplan-Meier survival curves were performed to assess the association between lncRNAs and clinical outcomes. Results: Among the 417 differentially expressed lncRNAs identified, three stood out: ENSG00000267838, ENSG00000266340, and FRMD6-AS1. High expression of ENSG00000267838 and ENSG00000266340 correlated with treatment resistance and a worse prognosis, while their low expression indicated a better therapeutic response. Kaplan-Meier analysis showed that high expression of these lncRNAs was associated with shorter progression-free survival. The decision tree model demonstrated high accuracy (87.09%) in distinguishing between responder and non-responder patients. Conclusions: Three lncRNAs, ENSG00000267838, ENSG00000266340, and FRMD6-AS1, were identified as being positively associated with non-response to chemoradiotherapy and poorer progression-free survival in CC patients. Specifically, the upregulation of lncRNA ENSG00000267838 was linked to treatment resistance, while its downregulation was associated with a favorable response to chemoradiotherapy.

23 October 2026 in Mário Penna Journal
Verified
Journal Article
Open access
PDF file
ANAngelo Borges de Melo Neto
Angelo Borges de Melo Neto
BDBruna Custódio Dias Duarte
Bruna Custódio Dias Duarte
MGMatheus de Souza Gomes
Matheus de Souza Gomes
Letícia Conceição BragaLetícia Conceição Braga
Letícia Conceição Braga
FQFabio Ribeiro Queiroz
Fabio Ribeiro Queiroz
Background: The overall 5-year survival rate for cervical cancer (CC) is low if diagnosed at an advanced stage, making it one of the most lethal cancers in the world. To this end, the World Health Organization has developed the 90-70-90 global strategy to eliminate CC in the coming Years (1). The search for new diagnostic and prognostic genetic signatures is essential in this fight. Objective: This study aims to identify potential biomarkers associated with metastasis and epithelial-mesenchymal transition (EMT) in CC. Methods: RNA sequencing of non-stem cancer cells (NSCCs) was performed, and adapters and low-quality sequences were trimmed. Then, the mapping reads, transcript, gene, and miRNA quantification, as well as the quantification of differentially expressed genes (DEGs), transcripts (DETs), and miRNAs (DEmiRNAs), were performed. Only genes and transcripts with significant expression profiles between 13 metastatic patients (M) and 8 with primary tumors (P) were selected. Finally, DEmiRNAs were chosen to target DEGs or DETs. The influence on overall survival of the patients was calculated by Kaplan-Meier (KM) analysis. Results: 9444 DETs, 2648 DEGs, and 178 DEmiRNAs were found, and these 16 DETs and 7 DEGs showed a strong regulation profile in groups. However, TCL6-206, LRRC1, and UBE2E1-AS1 were only overexpressed in the M patients. Similarly, in the literature, the lncRNA UBE2R2-AS1 and the gene UBE2E2 enhanced EMT in prostate and ovarian cancer (2), respectively, and the UBE2E1-AS1 was upregulated as a risky gene (HR>1) in the KM analysis. On the other hand, the LRRC1 (3) and TLC6-206 (4) were tumor suppressors in many cancers and, when overexpressed, increased the OS in the CC. Of 178 DEmiRNAs, LRRC1 was the target only from miR-222-5p. Conclusion: This is the first report about the association between TCL6-206 splice variant upregulation and metastasis, unlike your gene in the literature. Furthermore, the first study demonstrated an oncogenic role for LRRC1 as a potential target gene of this lncRNA and UBE2E1-AS1, with miR-222-5p identified as a potential competitive endogenous RNA (ceRNA).

23 October 2026 in Mário Penna Journal
Verified
Journal Article
Open access
PDF file
LFLarissa Paula Carvalho Ferreira
Larissa Paula Carvalho Ferreira
ANAngelo Borges de Melo Neto
Angelo Borges de Melo Neto
BDBruna Custódio Dias Duarte
Bruna Custódio Dias Duarte
LALaurence Rodrigues do Amaral
Laurence Rodrigues do Amaral
FQFábio Ribeiro Queiroz
Fábio Ribeiro Queiroz
Introduction: Cervical cancer (CC) remains one of the leading causes of cancer-related death among women, particularly in low- and middle-income countries. One of the main therapeutic challenges is resistance to chemoradiotherapy, often associated with specific molecular alterations. Strategies such as drug repurposing — the use of approved medications for new indications — have shown success in other malignancies and emerge as a promising alternative in CC. Previous studies identified the PNMA3 and RASSF2 genes as differentially expressed in non-responsive patients, suggesting their involvement in resistance mechanisms (1). Objectives: To investigate whether a functional interaction exists between PNMA3 and RASSF2 proteins in CC patients. If confirmed, to explore the therapeutic potential of repurposed drugs capable of modulating this interaction as a strategy to overcome therapeutic resistance. Materials and Methods: Protein sequences of PNMA3 and RASSF2 were retrieved from the UniProt database. Their 3D structures were refined and prepared using the Molecular Operating Environment (MOE) software. Functional domains were defined based on UniProt annotations and active site analysis using the Site Finder module. A total of 179 approved drugs were selected from the ChEMBL database based on bioactivity, AlogP, molecular weight, and clinical status. Molecular docking assays were conducted using the induced fit protocol in MOE. The docking protocol was previously validated by redocking the HIV-1 protease (PDB: 1HVR), with RMSD calculation. The most relevant interactions were subjected to 100 ps molecular dynamics simulations. Comparative graphs were generated to distinguish drugs exclusive to each protein or shared between both. Results: Structural analysis suggested that PNMA3 may associate with the SARAH domain of RASSF2, potentially blocking its interaction with MST1/MST2 kinases, key elements of the Hippo pathway, and apoptotic regulation. Among the evaluated drugs, Avanafil showed the highest affinity for PNMA3, while Risdiplam showed the most prominent affinity for RASSF2. Nebivolol hydrochloride demonstrated high exclusive affinity for PNMA3 with no detected interaction with RASSF2, indicating relevant functional selectivity. Redocking with HIV-1 protease confirmed protocol reliability (RMSD = 1.59 Å) (2). Discussion: The data support the hypothesis that PNMA3 may functionally inhibit RASSF2 by preventing its binding to MST1/MST2, thereby impairing Hippo pathway activation and apoptosis. Drug distribution across the targets reinforces this model, especially with the identification of selective compounds such as Nebivolol, which showed no interaction with RASSF2. These findings are consistent with previous reports describing RASSF2 as a K-Ras-specific effector involved in apoptotic regulation through Hippo signaling (3). These observations provide a rationale for functional validation of the PNMA3–RASSF2 interaction as a therapeutic target and for the rational repurposing of drugs as a strategy to overcome resistance in CC. Conclusion: A possible functional interaction between PNMA3 and RASSF2 was observed, suggesting that PNMA3 may negatively regulate the pro-apoptotic activity of RASSF2. Rational drug repurposing identified candidate compounds with selective affinity for PNMA3, particularly Nebivolol hydrochloride. These findings support the potential of a novel therapeutic target for treatment-resistant cervical cancer and justify further experimental validation.

27 July 2026 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
ANAngelo Borges de Melo Neto
Angelo Borges de Melo Neto
FQFábio Ribeiro Queiroz
Fábio Ribeiro Queiroz
CMCarolina Pereira de Souza Melo
Carolina Pereira de Souza Melo
BDBruna Custódio Dias Duarte
Bruna Custódio Dias Duarte
JFJorge Gomes Goulart Ferreira
Jorge Gomes Goulart Ferreira
MGMatheus de Souza Gomes
Matheus de Souza Gomes
Background: Cervical cancer (CC) is a main malignancy affecting women globally, with a high mortality rate. Chemoradiotherapy resistance is a significant factor in determining treatment outcomes, and prognostic biomarkers are essential for the appropriate selection of therapeutic strategies. This study aimed to identify gene expression signatures that may allow for follow‐up treatment response in CC patients. Methods: Samples of non‐stem CC cells selected by Fluorescence‐activated Cell Sorting from 21 Responders and 10 Non‐responder patients, who attended the Mario Penna Institute (Belo Horizonte—Brazil) from August 2017 to May 2018, and submitted to Next‐generation RNA sequencing, were analyzed to evaluate differential gene expression profiles between both groups. Machine Learning and statistical analyses were performed to identify a signature related to clinical outcomes. Results: 2670 Differentially expressed genes (DEGs) with log 2 FoldChange ≤ −1 or ≥ 1 and adjusted p ‐value ≤ 0.05 were found. Of these, 1591 were protein‐coding, but only 8 were considered relevant based on machine‐learning and statistical analyses for classifying treatment response. However, only PNMA3 and ZIK1 were markedly upregulated in non‐responder patients. Among the genes upregulated in Responder patients, only ATF4 and ATP1B3 were identified by machine‐learning analysis. On the other hand, only ATF4 , PNMA3 , and ZIK1 were associated in network interactions, more specifically to apoptosis pathways, and the differential expression of ATF4 and PNMA3 occurred exclusively in cervical cancer non‐stem cells, in the presence of ZIK1 . Conclusions: We propose that upregulation of PNMA3 and downregulation of ATF4 , specifically in cervical cancer non‐stem cells, is associated with upregulation of ZIK1 and with resistance to apoptosis and chemoradiotherapy. Therefore, suggesting that these genes may serve as potential signatures for CC prognosis.